Background: Pulmonary Mycobacterium avium complex (pMAC) disease is a chronic, slowly progressive disease. The aim of the present study was to determine the association of six-minute walk test (6MWT) parameters with pulmonary function and the health-related quality of life (HRQL) in patients with pMAC disease.
Background
The increasing prevalence of pulmonary infections due to nontuberculous mycobacteria (NTM) is an emerging public health concern worldwide [1, 2] . Pulmonary Mycobacterium avium complex (pMAC) disease, the most common form of NTM infection, presents as a chronic, slowly progressive disease in immunocompetent patients [3] . It causes chronic pulmonary diseases such as asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) and is generally incurable, requires long-term antimicrobial therapy, and has a high recurrence rate after treatment discontinuation [3] . Because of the increasing chronicity of pMAC disease, patient-reported outcome measures that represent the health-related quality of life (HRQL) have become increasingly important to monitor the overall health status of affected patients [4] . It has been reported that HRQL, particularly the physical component, is impaired in patients with pMAC [5] .
The six-minute walk test (6MWT) has become a useful tool for assessing the functional status and predicting the prognosis of patients with various pulmonary diseases, including COPD, ILD, sarcoidosis, and primary pulmonary hypertension [6] [7] [8] [9] . It is also used as a standardized exercise test for the assessment of lung disease because of its simplicity, low cost, non-invasiveness, ease of performance, and reproducibility [10, 11] . Recently, a randomized study of inhaled liposomal amikacin revealed an improvement in 6MWT parameters in patients with pNTM disease [12] . With regard to the clinical significance of 6MWT for pMAC disease, only one study has assessed the relationship between the six-minute walk distance (6MWD) and HRQL evaluated using St. George's Respiratory Questionnaire (SGRQ) [13] . However, the correlations between HRQL and various 6MWT parameters remain unknown.
The aim of the present study was to investigate the relationship of 6MWT parameters with clinical parameters, including pulmonary function test (PFT) findings, and HRQL. The tested hypothesis was that 6MWT parameters could be useful for evaluating HRQL in patients with pMAC disease.
Methods

Study design and study population
This cross-sectional study included adult patients with pMAC who were recruited from the prospective, observational cohort registry at Keio University Hospital (UMIN000007546). PMAC was diagnosed on the basis of statements published by the American Thoracic Society (ATS) and Infectious Disease Society of America in 2007 [3] . The Keio University Hospital institutional review board approved the study protocol (# 20110267), and written informed consent was obtained from each patient. All patients with pMAC who participated in 6MWT and completed questionnaires assessing HRQL between May 2012 and November 2013 were included.
6MWT
All patients were instructed to walk in a hallway for 6 min according to ATS guidelines [10] . Oxygen saturation by pulse oximetry (SpO 2 ) and heart rate (HR) were monitored throughout the 6-min walk. The total distance walked and the oxygen saturation and HR (per minute) measured from start to finish were recorded. The patients were assessed using the Borg Dyspnea Scale at the end of the test [14] . Other parameters such as the distance-saturation product (DSP) [6] and desaturation area (DA) [15] were also calculated.
HRQL assessments
For the evaluation of HRQL, all patients completed the 36-Item Short Form Health Survey (SF-36), version 2 [16] and SGRQ in Japanese [17] . Both these questionnaires have been validated for use in patients with pMAC disease [5] . The SF-36 comprises physical, mental, and role/social domains, and the respective summary scores were adjusted for Japanese patients [18] before analysis. All scores were transformed to fit a norm-based score of 50 and standard deviation of 10, and lower scores indicated a poorer health status. With regard to SGRQ (range, 0-100), we calculated the total score as well as scores for Symptoms, Activity, and Impacts domains, which evaluate respiratory symptoms, physical activity impairment, and social and psychological disturbances, respectively. Lower scores indicated a better health status.
Assessment of clinical parameters
Clinical parameters, including sex, age at diagnosis, disease duration, body mass index (BMI), smoking status, underlying pulmonary diseases, comorbidities assessed using the age-adjusted Charlson comorbidity index (CCI) [19] , and sputum smear and culture findings for MAC within the previous year were recorded at the time of enrolment. PFT was performed using an electronic spirometer (Chestac-9800 or HI-801; Chest M.I., Tokyo, Japan) when the patient was in a stable condition after study enrolment. MAC isolates were identified as previously described [20] . High-resolution computed tomography (HRCT) images were evaluated for cavitary lesions and the radiological pattern: nodular/ bronchiectatic (NB), fibrocavitary (FC), NB + FC, and unclassified [21] .
Statistical analysis
Correlations between two continuous variables were analyzed using Spearman's correlation coefficients.
Comparisons between two groups were conducted using the Wilcoxon rank sum test. To identify 6MWT parameters that predicted HRQL, parameters that showed a significant association with SGRQ and SF-36 scores in univariate analysis were entered into a stepwise forward and backward multiple regression model for multivariate analysis. All P-values were two-tailed, and a value of < 0.05 was considered statistically significant. All statistical analyses were conducted using JMP v11.0 (SAS Institute Japan Ltd., Tokyo, Japan).
Results
Patient characteristics and SF-36 and SGRQ scores
In total, 103 patients with pMAC were enrolled. Table 1 shows the clinical characteristics of the patients. The median [interquartile range (IQR)] age of patients was 68 (64-75) years. Eighty (78%) patients were women and 92 (89%) patients were never-smokers. Underlying pulmonary diseases were present in 16 (15%) patients. The median PFT values were within the normal range. On HRCT, 31 (30.1%) patients showed cavitary lesions, and the NB pattern was most commonly observed (81 patients, 78.6%). With regard to HRQL, the median scores for the physical and role/social domains in SF-36 were decreased, whereas the median Symptoms, Activity, and total scores in SGRQ were increased. (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) units. Table 3 shows Spearman's correlations among 6MWT parameters and clinical parameters for the 103 patients. 6MWD showed a strong correlation with DSP, DA, and the lowest SpO 2 . The initial SpO 2 was moderately correlated with the lowest SpO 2 or DA and the initial and final HRs. Age was significantly correlated with 6MWD, the FBS score, and DSP. Disease duration and age-adjusted CCI were also weakly correlated with the FBS score. Finally, the percentage functional volume Table 4 shows the correlations among 6MWT parameters or clinical parameters and SF-36 and SGRQ scores for the 103 patients. The physical component summary (PCS) score in SF-36 was strongly correlated with the Activity and total scores in SGRQ. The mental component summary (MCS) and role/social component summary (RCS) scores were also significantly correlated with the SGRQ scores, although the correlations were weaker than that of the PCS score. All SGRQ scores showed a significant negative correlation with 6MWD We also analyzed the data for the never smoker group (n = 92) alone in Additional file 1: Table S4 . Correlations among 6MWT parameters or clinical parameters and SF-36 and SGRQ scores were the same as that for all patients including former-smoker patients (n = 103). Comparisons of 6MWT parameters and questionnaire scores between patients with cavitary lesions and those without
6MWT parameters
Correlations among 6MWT parameters and clinical parameters
We also evaluated whether 6MWT parameters and the questionnaire scores differed between patients with cavitary lesions (n = 31, 30.1%) on HRCT and those without (n = 72, 69.9%; Additional file 1: Table S6 ), because cavitary lesions have been reported as a prognostic factor for pMAC disease [22, 23] . While 6MWT parameters except the initial HR showed no significant differences between the two groups, the Symptoms and Impacts scores in SGRQ were significantly higher in patients with cavitary lesions than in those without.
Multivariate analysis for predictors of SGRQ and SF-36 scores
We performed stepwise multiple regression analysis to determine the association of SGRQ and SF-36 scores with age, sex, age-adjusted CCI, BMI, smoking status, disease duration, underlying pulmonary diseases, positive sputum smear or culture findings, presence of cavitary lesions, pulmonary function, 6MWD, DSP, and the FBS score ( Table 5 ). The MCS and RCS scores were excluded because they only showed weak correlations with 6WMT parameters. We chose 6MWT parameters and clinical parameters for stepwise multiple regression analysis that showed significant correlations with SGRQ or SF-36 scores as shown in Table 4 or that were thought to be clinically important from previous studies. %FVC, sex, and BMI were found to be significant predictors of the Symptoms score in SGRQ, accounting for 21.2% variance, while DSP, the FBS score, and BMI were found to be significant predictors of the Activity score in SGRQ, accounting for 54.0% variance. The FBS score, %FVC, 6MWD, and BMI were found to be significant predictors of the Impacts score in SGRQ, accounting for 38.9% variance. The FBS score, 6MWD, BMI, and %FVC were found to be significant predictors of the SGRQ total score, accounting for 49.4% variance. Finally, the FBS score, 6MWD, age, sex, and disease duration were found to be significant predictors of the physical component summary (PCS) score in SF-36, accounting for 49.2% variance. We also analyzed the data for the never smoker group (n = 92) alone in Additional file 1: Table  S5 . Correlations among 6MWT parameters and SF-36 and SGRQ scores were the same as that of all patients including former-smoker patients (n = 103). Hence, it was concluded that 6MWD and the FBS score are useful 6MWT parameters for the prediction of HRQL in patients with pMAC disease in all patients, including the never smoker group (n = 92) and former-smoker patients (n = 103) ( Table 5) .
Discussion
In the present study, we evaluated the relationship of 6MWT parameters with clinical parameters, including PFT findings, and HRQL in patients with pMAC disease. The findings revealed that 6MWD and the FBS score showed strong correlations with the PCS score in SF-36 and all SGRQ scores except for the Symptoms score. Furthermore, %FVC and BMI, which weakly correlated with 6MWD and the FBS score, were important predictors of the SGRQ scores. The relationship between 6MWD, which is classically used as the primary outcome of 6MWT, and HRQL assessed using different tools (including SGRQ and SF-36) has been determined in patients with various chronic pulmonary diseases [24, 25] , and it was found to correlate negatively with the total SGRQ score in patients with COPD and ILD [26] [27] [28] . A previous study on pMAC disease reported that 6WMD significantly correlated with the Activity (ρ = − 0.45) and total (ρ = − 0.31) scores in SGRQ [13] , while in another study, 6MWD showed a significant positive correlation with the total SF-36 score (ρ = 0.37) in patients with sarcoidosis [29] . Consistent with findings in previous studies, our data demonstrated that 6MWD was significantly correlated with SGRQ scores and the PCS score in SF-36 and was one of the important predictors of HRQL according to multivariate analysis.
In addition to 6WMD, we found that the FBS score was also an important predictor of SGRQ scores and the PCS score in SF-36. Dyspnea reflects the physiology of exercise limitation as well as the impact of exercise limitation on daily life [30] . In addition, scores for dyspnea assessed using the Borg scale exhibit good reliability and are used as a marker of patient-reported fatigue that reflects a local muscle phenomenon as well as general fatigue in patients with chronic pulmonary diseases [14] . Previous studies reported a significant correlation between the FBS score and all SGRQ scores (ρ = 0.33-0.56) in patients with COPD [27] and the total SF-36 score (ρ = 0.45) in patients with sarcoidosis [29] .
Our multivariate analysis revealed that both 6MWD and the FBS score were important predictors of HRQL parameters. 6MWD is an objective parameter showing significant correlations with measures of peak work capacity in cardiopulmonary exercise tests [24] . Furthermore, a study on COPD revealed that 6MWD was associated with not only lung function but also lower limb strength, including quadriceps strength and the lean leg mass [31] . On the other hand, the Borg scale is a subjective parameter reflecting subjective breathlessness, perceived exertion, and fatigue [14, 24, 32] . A previous study on severe COPD and asthma indicated that the Borg scale could not be reliably predicted by desaturation and PFT findings [32] . In fact, a study on COPD indicated that both 6MWD and the FBS score were significant independent prognostic factors [33] . Thus, 6MWD reflects objective exercise tolerance better than does the FBS score, and both are useful parameters for the assessment of patients with pMAC disease. Our multivariate analysis also found that %FVC and BMI, which have been reported as important clinical factors in previous studies, were predictors of SGRQ scores [13, 20, 23] , [34, 35] . In a previous study, FVC showed a negative correlation with SGRQ scores [13] , consistent with the findings in this study. Moreover, a substantial decline in FEV 1 and FVC was associated with treatment failure in another study [34] . BMI has been reported as a poor prognostic factor for pulmonary NTM infection [20, 23, 35] . Notably, our results indicated partially significant but weak correlations among BMI, 6WMD or the FBS score, and PFT findings. Therefore, %FVC and BMI, in addition to 6MWD and the FBS score, may be useful parameters for clinical assessments, including HRQL evaluation.
Our study has several potential limitations. First, we may have excluded patients with more severe pMAC disease, considering we only included patients who could complete PFT, 6MWT, and HRQL questionnaires. Second, this was a cross-sectional study; therefore, we could not determine causal associations, particularly with regard to the influence of treatment. Third, our study mainly included female patients, consistent with the participants of previous studies about pMAC disease [1, [35] [36] [37] . Comparison between sexes shows significantly lower BMI in women (Additional file 1: Table S7 ); this may have affected our results, because BMI is a significant predictor of all SGRQ scores (Table 5) . Moreover, we could not evaluate the impact of 6MWT parameters on the prognosis. However, a shorter 6MWD is reported to be strongly correlated with an increased risk of mortality in patients with other chronic pulmonary diseases, including COPD, ILD, and pulmonary hypertension [24, 25, [38] [39] [40] . Therefore, we believe that 6MWT may be useful for the assessment of prognosis in patients with pMAC disease.
Conclusions
Our findings suggest that 6MWD and the FBS score are useful 6MWT parameters for the prediction of HRQL in patients with pMAC disease. However, further studies are needed to investigate the impact of 6WMT parameters on disease progression, treatment responses, and prognosis.
Additional file
Additional file 1: Supplemental analyses. Table S1 . Clinical characteristics of patients with pulmonary Mycobacterium avium complex disease in the never smoker group (n = 92). Table S2 . Results of the six-minute walk test for patients with pulmonary Mycobacterium avium complex disease in the never smoker group (n = 92). Table S3 . Spearman's correlations among six-minute walk test parameters and clinical parameters for patients with pulmonary Mycobacterium avium complex disease in the never smoker group (n = 92). 
